RxDoctor Payments Data

Laroy Williams, MD

Urology · Kearney, NENPI 1619904927

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,646 of the $6,371 with a category attached, or 88.6%. 49 manufacturers reported payments, led by Teleflex LLC at 27.1% of the total.

$6,371in general payments, 2019–2025

Across 272 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • AbbVie$585
  • Astellas Pharma US Inc$481
  • Johnson & Johnson$311
  • Bayer$294
  • Novartis$248
  • plus $3K from 43 others

What the payments were for

  • Travel & lodging$5709%
  • Food & beverage$5,64689%
  • Education$1552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,371 in reported general payments places this provider in the 65th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$389,260
Medicare patients
782
Services billed
5,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron140$55,678
Abiraterone Acetate23$37,992
Tamsulosin Hcl529$7,874
Solifenacin Succinate315$7,722
Trimethoprim80$4,389
Fesoterodine Fumarate ErFesoterodine Fumarate14$3,054
Finasteride150$2,306
NitrofurantoinNitrofurantoin Macrocrystal54$1,516
Bicalutamide45$747
Potassium Citrate ErPotassium Citrate12$715
Cephalexin79$619
Oxybutynin Chloride ErOxybutynin Chloride47$616
Megestrol Acetate25$293
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim76$284
Levofloxacin89$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$481$55,678140 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$28$37,99223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 79 urology providers in Nebraska.

Other urology in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →